Meeting
2021 ASCO Annual Meeting
Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.
Authors
Rebekah Rittberg
CancerCare Manitoba, Winnipeg, MB, Canada
Rebekah Rittberg , Oliver Bucher , Lin Xue , Zeb Aurangzeb , Shantanu Otto Banerji , David Dawe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9120)
DOI
10.1200/JCO.2021.39.15_suppl.9120
Abstract #
9120
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC).
First Author: Abdel-Ghani Azzouqa
Poster
2023 ASCO Quality Care Symposium
Healthcare contact days for patients with stage IV non-small cell lung cancer (NSCLC) in Ontario: A population-based study.
First Author: Arjun Gupta
Poster
2023 ASCO Annual Meeting
Treatment at twilight: Is less more in the management of octogenarians with non-small cell lung cancer (NSCLC)?
First Author: Ethan Burns
Poster
2023 ASCO Annual Meeting
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.
First Author: Jeffrey A. Scott